BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 25130198)

  • 21. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy.
    Gago FE; Fanelli MA; Ciocca DR
    J Steroid Biochem Mol Biol; 2006 Jan; 98(1):36-40. PubMed ID: 16188438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
    Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
    J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
    Hartkopf AD; Huober J; Volz B; Nabieva N; Taran FA; Schwitulla J; Overkamp F; Kolberg HC; Hadji P; Tesch H; Häberle L; Ettl J; Lux MP; Lüftner D; Wallwiener M; Müller V; Beckmann MW; Belleville E; Wimberger P; Hielscher C; Geberth M; Fersis N; Abenhardt W; Kurbacher C; Wuerstlein R; Thomssen C; Untch M; Fasching PA; Janni W; Fehm TN; Wallwiener D; Brucker SY; Schneeweiss A
    Breast; 2018 Feb; 37():42-51. PubMed ID: 29100043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: results of an observational study.
    Bighin C; Dozin B; Poggio F; Ceppi M; Bruzzi P; D'Alonzo A; Levaggi A; Giraudi S; Lambertini M; Miglietta L; Vaglica M; Fontana V; Iacono G; Pronzato P; Del Mastro L
    Oncotarget; 2017 Jul; 8(27):44800-44810. PubMed ID: 28108743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study.
    Cleeland CS; Mayer M; Dreyer NA; Yim YM; Yu E; Su Z; Mun Y; Sloan JA; Kaufman PA
    Breast; 2014 Dec; 23(6):763-9. PubMed ID: 25193423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies.
    Brufsky AM
    Cancer Treat Rev; 2017 Sep; 59():22-32. PubMed ID: 28719836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimizing the treatment of metastatic breast cancer.
    Gralow JR
    Breast Cancer Res Treat; 2005; 89 Suppl 1():S9-S15. PubMed ID: 15770536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The association between Akt activation and resistance to hormone therapy in metastatic breast cancer.
    Tokunaga E; Kataoka A; Kimura Y; Oki E; Mashino K; Nishida K; Koga T; Morita M; Kakeji Y; Baba H; Ohno S; Maehara Y
    Eur J Cancer; 2006 Mar; 42(5):629-35. PubMed ID: 16464571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Responses to primary systemic therapy for breast cancer as assessed by hormone receptor and HER2 status].
    Hirano A; Shimizu T; Kamimura M; Ogura K; Kim N; Setoguchi Y; Okubo F; Kinoshita J; Ogawa K; Fujibayashi M
    Gan To Kagaku Ryoho; 2011 May; 38(5):771-6. PubMed ID: 21566435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.
    Hao Y; Meyer N; Song X; Shi N; Johnson W; Juneau P; Yardley DA; Willemann Rogerio J
    Curr Med Res Opin; 2015 Feb; 31(2):275-88. PubMed ID: 25365467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
    Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
    J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer.
    Paplomata E; Zelnak A; Santa-Maria CA; Liu Y; Gogineni K; Li X; Moreno CS; Chen Z; Kaklamani V; O'Regan RM
    Clin Breast Cancer; 2019 Jun; 19(3):188-196. PubMed ID: 30745109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.
    Fabi A; Russillo M; Ferretti G; Metro G; Nisticò C; Papaldo P; De Vita F; D'Auria G; Vidiri A; Giannarelli D; Cognetti F
    BMC Cancer; 2012 Oct; 12():482. PubMed ID: 23083011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.
    Alvarez-Lopez I; Bezares S; Dalmau Portulas E; García-Martínez E; García-Sáenz JÁ; Gil-Gil M; Martínez de Dueñas E; Ribelles N; Santaballa Bertrán A
    Clin Transl Oncol; 2020 Aug; 22(8):1364-1377. PubMed ID: 32052382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
    Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.